Shannon Turley

First Name*

Last Name*

Email*

Phone*

Message*

I am authorized to claim this profile. I agree Eventually may contact me regarding my request.

Your request has been received.
Thank you.

Oops! Something went wrong while submitting the form.

First Name*

Last Name*

Email*

Phone*

Message*

Shannon Turley and Eventually may contact me regarding my request.

Your request has been received.
Thank you.

Oops! Something went wrong while submitting the form.

Contact Shannon

Shannon Turley

Vice President and Therapeutic Area Head, Immunology and Regenerative Medicine

Genentech

Dr. Turley is the Vice President of Cancer Immunology Discovery, Senior Fellow and Cancer Immunology Therapeutic Area Head at Genentech. where she oversees the Cancer Immunotherapy portfolio including early stage research to early clinical development. Prior to joining Genentech in 2014, Dr. Turley served on the faculty at Dana Farber Cancer Institute (DFCI) and Harvard Medical School (HMS) as well as the Associate Director of the Harvard PhD Program in Immunology. Dr. Turley has extensive experience in research and drug development focused on stromal, immune and tissue biology in cancer, fibrosis, inflammation and autoimmune diseases. Dr. Turley received her PhD from Yale University School of Medicine and postdoctoral training at Joslin Diabetes Center at Harvard Medical School.

Talks About
#immunology #management

Preferred Locations
#Northamerica

Speaking Engagements

2nd TGFB for Immuno-Oncology Drug Development

Paid

The Leading TGF-ß for Immuno-Oncology Summit Returns Exclusively Dedicated to Exploring the Role of TGF-ß in Cancer Therapeutics It is evident that TGF-ß holds exciting therapeutic promise to IO drug developers but with the complexity of this target, there are still many hurdles to overcome.

25-27 January 2022

Healthcare

Antifibrotic Drug Development Summit (AFDD)

Paid

Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF, NASH, CKD and more in one place at one time, so you can advance the progress of your antifibrotic therapies.

09-11 November 2022

Healthcare

Antibody Engineering & Therapeutics US

Paid

The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Degraders, Immuno-oncology, T-Cells, VHH and much more...

13-16 December 2023

Healthcare

Claim Your Profile Request

Speaker Contact Request

SPEAKER

Shannon Turley

Vice President and Therapeutic Area Head, Immunology and Regenerative Medicine

Speaking Engagements

2nd TGFB for Immuno-Oncology Drug Development

Antifibrotic Drug Development Summit (AFDD)

Antibody Engineering & Therapeutics US